Charles Schwab Investment Management Inc. Has $12.51 Million Stock Holdings in Dynavax Technologies Co. (NASDAQ:DVAX)

Charles Schwab Investment Management Inc. cut its holdings in Dynavax Technologies Co. (NASDAQ:DVAX) by 1.3% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,122,733 shares of the biopharmaceutical company’s stock after selling 14,840 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately 0.86% of Dynavax Technologies worth $12,507,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Dynavax Technologies by 1.0% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 118,037 shares of the biopharmaceutical company’s stock valued at $1,326,000 after acquiring an additional 1,172 shares during the last quarter. SummerHaven Investment Management LLC increased its holdings in Dynavax Technologies by 2.4% in the second quarter. SummerHaven Investment Management LLC now owns 54,926 shares of the biopharmaceutical company’s stock worth $617,000 after purchasing an additional 1,303 shares in the last quarter. Nisa Investment Advisors LLC lifted its stake in Dynavax Technologies by 44.6% in the third quarter. Nisa Investment Advisors LLC now owns 5,441 shares of the biopharmaceutical company’s stock valued at $61,000 after buying an additional 1,679 shares during the period. GAMMA Investing LLC boosted its holdings in shares of Dynavax Technologies by 175.5% during the 3rd quarter. GAMMA Investing LLC now owns 2,645 shares of the biopharmaceutical company’s stock worth $29,000 after buying an additional 1,685 shares in the last quarter. Finally, Louisiana State Employees Retirement System lifted its position in shares of Dynavax Technologies by 3.0% during the 2nd quarter. Louisiana State Employees Retirement System now owns 65,900 shares of the biopharmaceutical company’s stock valued at $740,000 after acquiring an additional 1,900 shares during the period. Institutional investors own 96.96% of the company’s stock.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $29.00 target price on shares of Dynavax Technologies in a research report on Friday, November 8th.

Dynavax Technologies Price Performance

NASDAQ DVAX opened at $12.85 on Monday. The firm’s 50-day simple moving average is $11.85 and its two-hundred day simple moving average is $11.44. The company has a market cap of $1.69 billion, a PE ratio of 98.85 and a beta of 1.33. Dynavax Technologies Co. has a 52 week low of $9.74 and a 52 week high of $15.01. The company has a quick ratio of 12.34, a current ratio of 13.23 and a debt-to-equity ratio of 0.33.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.